Leo Pharma acquires Bayer prescription dermatology portfolio

Jul 31, 2018

Bayer will sell its prescription dermatology brands to Denmark’s Leo Pharma, as Bayer will shift its focus to its own drug development pipeline as well as integrating Monsanto.

According to both companies, the portfolio includes prescription skin creams against acne, fungal skin infections and rosacea, as well as some steroidal creams with 2017 revenues exceeding $328 million.

The deal does not include Bayer's over-the-counter brands.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments